Goldman Sachs Group Inc (GS) stock saw a decline, ending the day at $636.9 which represents a decrease of $-2.60 or -0.41% from the prior close of $639.5. The stock opened at $630 and touched a low of $628.

Goldman Sachs and UBS have emerged as the leading mergers and acquisitions (M&A) financial advisers in South America for 2024, in terms of deal value and volume, respectively, according to the latest league table from GlobalData, a data and analytics firm.

UBS analyst Brennan Hawken raised the firm’s price target on Goldman Sachs (GS) to $640 from $610 and keeps a Neutral rating on the shares. The

UBS Chief Executive Sergio Ermotti on Tuesday said it was currently premature for the Swiss bank to consider acquisitions as it continues to focus on the integration of Credit Suisse, which it bought in 2023.

Goldman Sachs (NYSE: GS) shares traded higher after reporting strong Q4 and full-year 2024 results. Revenue, EPS, and stock buybacks all beat expectations.

J.P. Morgan analyst Kian Abouhossein maintained a Buy rating on Goldman Sachs Group (GS – Research Report) today. The company’s shares opened

Goldman Sachs came third in this category with 179 deals, followed by UBS with 166 deals, and JP Morgan with 161 deals. In the deal value rankings, JP Morgan claimed the second spot by advising on ...

Analyst Ratings: In the last 15 days, Oppenheimer lowered Goldman Sachs stock price forecast from $677 to $639, UBS downgraded the stock to a Neutral rating with a price forecast of $610 ...

The Goldman Sachs Group (NYSE:GS – Free Report) had its target price increased by UBS Group from $610.00 to $640.00 in a report issued on Tuesday morning,Benzinga reports.UBS Group currently has ...

Goldman Sachs CEO David Solomon promoted a slew of top bankers on Tuesday to run the firm’s biggest business units, just days after the bank boss was awarded a pair of massive bonuses.

Goldman Sachs on Monday tapped veteran banker Stefan Duffner to lead the investment bank's activism and shareholder advisory work in Europe, Middle East and Africa (EMEA) at a time corporations are increasingly asking for help to defend against activist investors pushing for changes.

Piper Sandler adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) shares, reducing it from the previous $1,195.00 to $1,013.00. Despite this change, the firm maintained its Overweight rating on the biotech company's stock.